FDA Inspection 1304780 — Novartis Pharmaceutical Manufacturing GmbH
The FDA completed an inspection of Novartis Pharmaceutical Manufacturing GmbH on January 27, 2026 in Kundl. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- January 27, 2026
- Fiscal Year
- 2026
- Product Type
- Biologics
- Project Area
- Vaccines and Allergenic Products
- Location
- Kundl (Austria)